Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Acacia Pharma Group    ACPH   GB00BYWF9Y76

ACACIA PHARMA GROUP

(ACPH)
  Report  
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
05/16/2019 05/17/2019 05/20/2019 05/21/2019 05/22/2019 Date
1.744(c) 1.7(c) 1.68(c) 1.712(c) 1.666 Last
112 580 59 813 33 720 31 355 52 466 Volume
+0.11% -2.52% -1.18% +1.90% -2.69% Change
More quotes
Financials (GBP)
Sales 2019 1,11 M
EBIT 2019 -46,0 M
Net income 2019 -44,4 M
Debt 2019 -
Yield 2019 -
Sales 2020 13,5 M
EBIT 2020 -42,0 M
Net income 2020 -40,4 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020
Capi. / Sales2019 71,1x
Capi. / Sales2020 5,82x
Capitalization 78,6 M
More Financials
Company
Acacia Pharma Group specializes in the research and development of supportive care medicines. The products are intended to support the side effects of anti-cancer treatments (including nausea and vomiting drugs). At the end of 2018, the group had a portfolio of 2 products, including APD403 in... 
Sector
Pharmaceuticals
Calendar
06/03 | 06:00amShareholder meeting
More about the company
Latest news on ACACIA PHARMA GROUP
05/11ACACIA PHARMA : Pharmas BARHEMSYS Significantly Improves Post-operative Nausea &..
AQ
05/10ACACIA PHARMA : BARHEMSYS Significantly Improves Post-operative Nausea & Vomitin..
AQ
05/08ACACIA PHARMA : Notice of Annual General Meeting
AQ
05/07ACACIA PHARMA : Notice of annual general meeting
AQ
05/06ACACIA PHARMA : Receives Complete Response Letter from Fda for Barhemsys
AQ
05/03ACACIA PHARMA : Receives Complete Response Letter From Fda for Barhemsys®
AQ
04/26ACACIA PHARMA : Announces Positive Phase 3 Barhemsys Rescue Treatment Data to be..
AQ
04/26ACACIA PHARMA : Announces Positive Phase 3 BARHEMSYS Rescue Treatment Data to be..
AQ
04/25ACACIA PHARMA : Announces positive phase 3 barhemsys® rescue treatment data to b..
AQ
02/28ACACIA PHARMA : Results for the year ended 31 December 2018
AQ
More news
Sector news : Pharmaceuticals - NEC
02:48aSANOFI : French Deal Spree Fueled By Easy Money
DJ
05/21UPDATE : N.Y. Jury Delivers $25 Million Judgment Against Johnson & Johnson -- Bl..
DJ
05/21JOHNSON & JOHNSON : Correction to Johnson & Johnson Jury Story
DJ
05/21JOHNSON & JOHNSON : N.Y. Jury Delivers $25 Million Judgment Against Johnson & Jo..
DJ
05/21BAYER : hires law firm to probe Monsanto data collection
RE
More sector news : Pharmaceuticals - NEC
Chart ACACIA PHARMA GROUP
Duration : Period :
Acacia Pharma Group Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACACIA PHARMA GROUP
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Managers
NameTitle
Gilbert Julian Clive Chief Executive Officer & Director
Scott A. Byrd Non-Executive Director
Patrick Volkert Vink Non-Executive Chairman
Christine Helen Soden Chief Financial Officer, Secretary & Director
Gabriel Fox Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ACACIA PHARMA GROUP33.77%100
JOHNSON & JOHNSON7.26%367 513
PFIZER-4.54%231 237
ROCHE HOLDING LTD.9.26%226 839
NOVARTIS11.63%207 417
MERCK AND COMPANY3.23%203 088